Want to see HK:9686 full AI Analyst Report?
Top Page
NEUSOFT XIKANG HOLDINGS INC.
(9686)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.93
▲(3.33% Upside)
Action:Reiterated
Date:09/06/26
The score reflects improving fundamentals (strong TTM revenue rebound and a shift to positive operating/free cash flow) but is held back by continued net losses and elevated leverage. Technicals add support with a clear uptrend and positive momentum, while valuation is pressured by a negative P/E and no dividend yield data.
Positive Factors
Revenue rebound
The sharp TTM revenue rebound indicates improving demand and renewed top-line momentum after two years of contraction. If sustained, stronger revenue can improve operating leverage, support reinvestment, and provide a larger base from which management can complete the broader turnaround.
Negative Factors
Persistent unprofitability
The company has not yet converted improved demand into sustainable operating profitability. Negative EBIT and EBITDA mean gross profit remains insufficient to cover operating costs, leaving earnings vulnerable if growth slows and limiting internally generated funds available for strategic investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp TTM revenue rebound indicates improving demand and renewed top-line momentum after two years of contraction. If sustained, stronger revenue can improve operating leverage, support reinvestment, and provide a larger base from which management can complete the broader turnaround.
Read all positive factors
NEUSOFT XIKANG HOLDINGS INC. (9686) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$825.04M
Dividend YieldN/A
Average Volume (3M)12.60K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue Growth-3.77%
EPS Growth73.89%
CountryHK
Employees763
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding841,877,800
10 Day Avg. Volume4,250
30 Day Avg. Volume12,600
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)2.17
Price to Sales (P/S)1.47
P/FCF Ratio45.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NEUSOFT XIKANG HOLDINGS INC. Business Overview & Revenue Model
Company Description
Xikang Cloud Hospital Holdings Inc. specializes in constructing customized digital healthcare platforms designed for urban settings. Its business operations are structured into four main categories: Cloud Hospital Platform Services, Internet Medic...
How the Company Makes Money
Detailed, reliable information on NEUSOFT XIKANG HOLDINGS INC. (9686) revenue model, key revenue streams, and significant partnerships is not available in the provided context; null...
NEUSOFT XIKANG HOLDINGS INC. Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
41
Neutral
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 468.40M | 464.14M | 501.50M | 537.72M | 687.41M | 614.30M |
| Gross Profit | 130.61M | 126.96M | 147.50M | 164.61M | 168.45M | 170.23M |
| EBITDA | -6.93M | -23.33M | -52.06M | -75.65M | -161.41M | -214.71M |
| Net Income | -17.47M | -38.93M | -83.05M | -154.65M | -241.97M | -296.54M |
Balance Sheet | ||||||
| Total Assets | 1.02B | 1.14B | 1.26B | 1.40B | 934.45M | 946.85M |
| Cash, Cash Equivalents and Short-Term Investments | 662.49M | 760.09M | 797.70M | 822.67M | 351.76M | 364.91M |
| Total Debt | 491.53M | 518.78M | 574.47M | 603.44M | 573.44M | 456.28M |
| Total Liabilities | 753.04M | 827.90M | 892.31M | 964.28M | 1.38B | 1.21B |
| Stockholders Equity | 270.67M | 313.54M | 363.31M | 428.14M | -451.98M | -274.55M |
Cash Flow | ||||||
| Free Cash Flow | 39.45M | 14.93M | 21.56M | -24.42M | -81.17M | -101.77M |
| Operating Cash Flow | 40.86M | 20.26M | 21.56M | -20.16M | -73.83M | -83.38M |
| Investing Cash Flow | -10.78M | -153.83M | 110.45M | -146.60M | -8.45M | -5.47M |
| Financing Cash Flow | -52.35M | -67.22M | -56.56M | 504.77M | 64.62M | 64.90M |
NEUSOFT XIKANG HOLDINGS INC. Technical Analysis
Positive
0.90
Price Trends
0.88
Positive
0.92
Positive
0.91
Positive
Market Momentum
0.02
Negative
82.06
Negative
93.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9686, the sentiment is Positive. The current price of 0.9 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.88, and below the 200-day MA of 0.91, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 82.06 is Negative, neither overbought nor oversold. The STOCH value of 93.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9686.
NEUSOFT XIKANG HOLDINGS INC. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$336.40M | 9.78 | 4.28% | 8.25% | -2.78% | -24.77% | |
56 Neutral | HK$1.18B | 86.19 | 0.48% | 0.99% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$825.04M | -46.77 | -5.98% | ― | -3.77% | 73.89% | |
49 Neutral | HK$785.44M | -10.75 | -5.98% | ― | 10.67% | 57.27% | |
46 Neutral | HK$503.71M | -1.28 | -25.36% | 1.47% | -8.94% | -140.82% |
* Healthcare Sector Average
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
1.00
>-0.01
-0.50%
HK:2138
EC Healthcare
0.44
-0.38
-46.95%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
8.80
-6.36
-41.95%
HK:2279
Yonghe Medical Group Co., Ltd.
2.02
-0.62
-23.56%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-30.92%
HK:0722
UMP Healthcare Holdings Limited
0.40
-0.05
-11.50%
NEUSOFT XIKANG HOLDINGS INC. Corporate Events
Xikang Cloud Hospital Narrows Loss as Policy Tailwinds Support AI-Enabled Healthcare Expansion
Aug 26, 2026
Xikang Cloud Hospital Holdings reported interim revenue of RMB182.9 million for the six months ended June 30, 2026, a 2.4% year-on-year increase, with gross margin improving to 23.5% and net loss narrowing by 45.1% to RMB27.4 million. The improvem...
Xikang Cloud Hospital Moves Long-Term Idle Listing Proceeds into Low-Risk Wealth Products
Aug 26, 2026
Xikang Cloud Hospital Holdings Inc. has disclosed that actual deployment of its listing proceeds lagged earlier expectations, leaving idle funds of about HK$496.5 million at end-2024 and HK$358.4 million at end-2025, well above its original projec...
Xikang Cloud Hospital Sets August Board Meeting to Review Interim Results
Aug 14, 2026
Xikang Cloud Hospital Holdings Inc. has scheduled a board meeting for 26 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider the possible recommendation of an interim ...
Xikang Cloud Hospital Grants 32.8 Million Share Options Under Post-IPO Scheme
Jul 23, 2026
Xikang Cloud Hospital Holdings Inc. has granted 32,785,000 share options to 195 eligible participants under its Post-IPO Share Option Scheme, with each option entitling the holder to subscribe for one ordinary share at an exercise price of HK$0.86...
Xikang Cloud Hospital to Deploy Idle IPO Funds into Low-Risk Cash Management
Jun 12, 2026
Xikang Cloud Hospital Holdings Inc. has resolved to continue deploying part of its idle proceeds from its HK$554.5 million global offering into low-risk, highly liquid wealth management products for cash management purposes. The board has approved...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.